What is the current Drugs for HAE market size?

The Drugs for HAE market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Drugs for HAE market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033, driven by increasing demand.

What are the key drivers of the Drugs for HAE market?

Key drivers include rising prevalence of Hereditary Angioedema and advancements in treatment options, shaping the future outlook.

What are the major challenges facing the Drugs for HAE market?

Challenges include high treatment costs and limited awareness, impacting the market's overall growth potential.

Which regions are leading the Drugs for HAE market?

North America and Europe are regional leaders, accounting for a significant share of the global market size.

Who are the top companies in the Drugs for HAE market?

Top companies include pharmaceutical giants such as Shire, CSL Behring, and BioCryst, driving innovation and growth.

What future opportunities exist in the Drugs for HAE market?

Opportunities include emerging markets and novel therapies, offering a promising future outlook for investors and stakeholders.

How is technology impacting the Drugs for HAE market?

Technology is enhancing diagnosis, treatment, and patient outcomes, with advancements in healthcare IT and medical devices.

What is the current regulatory landscape for the Drugs for HAE market?

The regulatory landscape is evolving, with ongoing efforts to improve approval processes and patient access to effective treatments.

How will the Drugs for HAE market evolve in the next 5 years?

The market will experience significant growth, driven by increasing awareness, new product launches, and expanding treatment options.

How Big Is the Drugs for HAE Market? Size, Share & Forecast 2033

Drugs for HAE by Application (Hospital and Clinic, Pharmacy, Other), by Types (C1 Esterase Inhibitors, Kallikrein Inhibitors, Bradykinin Receptor Antagonist), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 8.1%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 80

Forecast Period: 2026 - 2033

Market Size: $4.8 million

CAGR: 8.1%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Drugs for HAE Market Overview

The Drugs for Hereditary Angioedema (HAE) market is a crucial segment of the pharmaceutical industry, driven by the growing need for effective treatments to manage this rare and debilitating condition. As the global healthcare landscape continues to evolve, the Drugs for HAE market size is estimated to be approximately $2.5 billion in 2025, with a growth outlook that is expected to drive significant industry expansion. The market forecast suggests a compound annual growth rate (CAGR) of around 8-10% during the forecast period, driven by macro drivers such as increasing disease awareness, advancements in treatment options, and rising healthcare expenditure. The scope of this market encompasses a range of products, including plasma-derived C1 esterase inhibitors, recombinant C1 esterase inhibitors, and bradykinin receptor antagonists, among others.

Loading chart…

Key forces shaping the Drugs for HAE industry include technology shifts towards more targeted and personalized therapies, regulatory environments that encourage innovation and competition, and consumer behavior that demands greater accessibility and affordability of treatments. The largest region for the Drugs for HAE market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by rising healthcare spending and increasing awareness of HAE. As the market continues to evolve, it is essential for stakeholders to stay informed about the latest trends, challenges, and opportunities in this dynamic and rapidly expanding industry.

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	8.95 million
Growth rate	CAGR of 8.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda Pharmaceuticals; BioCryst Pharmaceuticals; CSL Behring; Pharming Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Drugs for HAE market is poised for significant growth, driven by increasing awareness and understanding of Hereditary Angioedema (HAE). The Drugs for HAE market size is expected to expand substantially, with a promising growth forecast. This section outlines the key dynamics shaping the market.

Growth Drivers2 items

Advancements in treatment options, such as the development of novel therapies and formulations, are expected to drive growth in the Drugs for HAE market. These innovations aim to improve patient outcomes and quality of life, thereby increasing demand for effective treatments.

Growing investments in research and development by pharmaceutical companies, coupled with rising collaborations and partnerships, are anticipated to fuel the expansion of the Drugs for HAE market. These strategic initiatives are likely to lead to the discovery of new drugs and therapies, further boosting market growth.

Restraints2 items

High development costs and stringent regulatory requirements may hinder the growth of the Drugs for HAE market. The complexity and expense associated with bringing new drugs to market can discourage investment and limit the entry of new players.

The Drugs for HAE market may also face challenges due to patent expirations and the subsequent entry of generic drugs, which can lead to increased competition and reduced prices. This may negatively impact the revenue growth of pharmaceutical companies.

Opportunities2 items

The increasing prevalence of HAE, combined with rising awareness and diagnosis rates, presents significant opportunities for growth in the Drugs for HAE market. As more patients seek treatment, the demand for effective drugs is likely to increase, driving market expansion.

Emerging markets, particularly in Asia-Pacific and Latin America, offer untapped opportunities for pharmaceutical companies to expand their presence and distribution networks. This can be achieved through strategic partnerships, investments, and regulatory approvals.

Challenges2 items

The Drugs for HAE market faces challenges related to pricing pressures and reimbursement issues, which can impact the profitability of pharmaceutical companies. The need to balance affordability with the high development costs of drugs can be a significant hurdle.

Ensuring supply chain resilience and regulatory compliance is crucial for companies operating in the Drugs for HAE market. This requires significant investment in infrastructure, quality control, and compliance measures to mitigate risks and maintain a stable supply of drugs.

Market Segmentation

Loading chart…

The Application segment of the Drugs for HAE market refers to the various uses of these medications in treating Hereditary Angioedema (HAE). This segment is crucial in understanding the Drugs for HAE segmentation, as it highlights the different areas where these drugs are applied, such as prophylaxis, acute treatment, and diagnostic testing. The application segment contributes significantly to the overall market size, with each application area having its own set of requirements and preferences, driving the demand for specific types of drugs.

The Types segment of the Drugs for HAE market encompasses various subtypes, including [object Object] and [object Object]. This segmentation is vital in understanding the market taxonomy, as it categorizes the drugs based on their active ingredients, mechanisms of action, and administration routes. The types segment plays a significant role in determining the market size, with each subtype having its own market share and growth prospects. The subtypes differ in their efficacy, safety profiles, and patient preferences, making this segmentation essential for industry stakeholders to develop targeted strategies.

Drugs for HAE Segmentation Breakdown8 items

Application

Hospital and Clinic

Pharmacy

Other

Types

C1 Esterase Inhibitors

Kallikrein Inhibitors

Bradykinin Receptor Antagonist

Regional Insights

Loading chart…

The Drugs for HAE market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the market share. The fastest-growing region is anticipated to be Asia Pacific, driven by increasing adoption of new treatments, favorable policies, and significant investments in healthcare infrastructure.

Key drivers for North America include a mature ecosystem, high demographics awareness, and established infrastructure. In Europe, drivers include favorable policies, a strong ecosystem, and significant investments in research and development. Asia Pacific is driven by increasing adoption, large demographics, and growing infrastructure. Latin America and Middle East & Africa are driven by improving infrastructure, increasing adoption, and government policies supporting healthcare development.

The regional forecast indicates that the Drugs for HAE market will experience significant growth in the coming years, with the Asia Pacific region expected to drive much of this growth. Understanding the key drivers and factors influencing each region is crucial for stakeholders to capitalize on emerging opportunities and navigate challenges in the Drugs for HAE market.

Competitive Landscape

The Drugs for HAE market is moderately consolidated, driven by a mix of global players and local companies. The Drugs for HAE competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on premium pricing and strong distribution networks, while local companies emphasize cost advantages and customization.

Companies employ various strategies to differentiate themselves, including M&A, partnerships, product launches, expansion, R&D, and localization. However, they face challenges such as margin pressure, compliance costs, and supply chain risks. Competitive differentiation is achieved through technology, service model, channel strength, and cost advantages. The following companies have distinct strategic focuses:

Takeda Pharmaceuticals: regional expansion

BioCryst Pharmaceuticals: innovation pipeline

CSL Behring: premium pricing

Pharming Healthcare: local manufacturing

Takeda Pharmaceuticals: vertical integration

BioCryst Pharmaceuticals: OEM tie-ups

Key Drugs for HAE Companies4 items

Takeda Pharmaceuticals

BioCryst Pharmaceuticals

CSL Behring

Pharming Healthcare

Market Ecosystem

The Drugs for HAE ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream end users, with value created and captured at various points along the way. This ecosystem can be broadly segmented into three key areas: upstream, where raw materials and components are sourced; midstream, where these inputs are integrated into finished products; and downstream, where these products are distributed and consumed. Understanding the Drugs for HAE ecosystem through a value chain analysis is crucial for identifying key control points, dependency risks, and opportunities for innovation.

Raw material suppliers — providing active pharmaceutical ingredients

OEMs/manufacturers — producing finished drug products

Technology providers — developing drug delivery systems

Distributors/channel partners — delivering products to healthcare providers

Service providers/after-sales — offering patient support services

Regulators/standards bodies — overseeing drug approvals and compliance

End users/buyers — patients and healthcare professionals

In the Drugs for HAE ecosystem, control points are largely influenced by regulators and standards bodies, as they dictate the approval and compliance frameworks that drug manufacturers must adhere to. Dependency risks arise from input constraints, such as the availability of active pharmaceutical ingredients, and from the need for approvals from regulatory bodies. Switching costs for end users can be high due to the specialized nature of HAE treatments, and partnerships between manufacturers and healthcare providers can be critical in ensuring access to these drugs. The ecosystem's structure and dynamics can vary by region, reflecting differences in healthcare systems, regulatory environments, and patient needs.

Recent Industry Insights

The Drugs for HAE industry has witnessed significant developments over the last 12-18 months, shaping the future of the market. Recent partnerships, such as collaborations between pharmaceutical companies and research institutions, have accelerated the development of innovative treatments. The industry has also seen notable mergers and acquisitions, further consolidating the market and driving growth. Additionally, several product launches have expanded the range of available treatments, catering to the diverse needs of patients. Regulatory changes have also played a crucial role, with updated guidelines and approvals influencing the Drugs for HAE industry trends. Furthermore, shifts in consumer preferences and enterprise trends have led to increased funding rounds and expansions, supporting the development of new therapies and technologies.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Drugs for HAE market outlook. The market attractiveness is moderate, driven by a growing patient population and increasing awareness of Hereditary Angioedema (HAE). The competitive intensity is high, with several established players and new entrants vying for market share. The long-term outlook is positive, with opportunities for innovation in treatment options and diagnostics.

The innovation landscape is evolving, with a focus on novel therapies and personalized medicine. However, the demand–supply balance is a concern, with some regions experiencing shortages of certain drugs. Key risk factors include regulatory changes, pricing pressures, and patient access to treatment. Overall, the Drugs for HAE market presents opportunities for growth, but also requires careful navigation of the competitive and regulatory landscape.

12 items

1. Executive Summary

2. Drugs for HAE Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Drugs for HAE Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Drugs for HAE Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Drugs for HAE Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Drugs for HAE Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Drugs for HAE Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Drugs for HAE Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Drugs for HAE Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Drugs for HAE Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Drugs for HAE Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Drugs for HAE Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Drugs for HAE Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Drugs for HAE Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Drugs for HAE Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Drugs for HAE Market Competition by Key Manufacturers

9.1. Global Drugs for HAE Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Drugs for HAE: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Takeda Pharmaceuticals

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. BioCryst Pharmaceuticals

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. CSL Behring

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Pharming Healthcare

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Drugs for HAE Market

Figure 4: Global Drugs for HAE Market: Drivers

Figure 5: Global Drugs for HAE Market: Challenges

Figure 6: Global Drugs for HAE Market: Trends

Figure 7: Global Drugs for HAE Market: Opportunity

Figure 8: Global Drugs for HAE Market: Restraint

Figure 9: Global Drugs for HAE Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Drugs for HAE Market Value (USD Million) By Region

Figure 19: Global Drugs for HAE Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Drugs for HAE Market Value (USD Million) By Region

Figure 27: Global Drugs for HAE Market Share (%) By: Regions (2032)

Figure 28: Global Drugs for HAE Market Volume (K) By Region

Figure 29: Global Drugs for HAE Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Drugs for HAE Market Value (USD Million) By Region

Figure 37: Global Drugs for HAE Market Share (%) By: Regions (2032)

Figure 38: Global Drugs for HAE Market Volume (K) By Region

Figure 39: Global Drugs for HAE Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

103 items

Table 1: Market Segmentation Analysis

Table 2: Global Drugs for HAE Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Drugs for HAE Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Drugs for HAE Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Drugs for HAE Market Value (USD Million) By Region

Table 14: Global Drugs for HAE Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Drugs for HAE Market Volume (K) By Region

Table 31: Global Drugs for HAE Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Drugs for HAE Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Drugs for HAE Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Drugs for HAE Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Takeda Pharmaceuticals Basic Information And Sales Area

Table 52: Takeda Pharmaceuticals. Products Portfolio

Table 53: BioCryst Pharmaceuticals Basic Information And Sales Area

Table 54: BioCryst Pharmaceuticals. Products Portfolio

Table 55: CSL Behring Basic Information And Sales Area

Table 56: CSL Behring. Products Portfolio

Table 57: Pharming Healthcare Basic Information And Sales Area

Table 58: Pharming Healthcare. Products Portfolio

Table 59: Global Market Value (USD Million) (2025-2032) By Application

Table 60: Global Market Share (%) By Application (2032)

Table 61: Global Market Value (USD Million) (2025-2032) By Types

Table 62: Global Market Share (%) By Types (2032)

Table 63: Global Market Volume (K) (2025-2032) By Application

Table 64: Global Market Share (%) By Application (2032)

Table 65: Global Market Volume (K) (2025-2032) By Types

Table 66: Global Market Share (%) By Types (2032)

Table 67: Global Drugs for HAE Market Value (USD Million) By Region

Table 68: Global Drugs for HAE Market Share (%) By Region (2025-2032)

Table 69: North America Market Value (USD Million) (2025-2032) By Country

Table 70: North America Market Value (USD Million) (2025-2032) By Application

Table 71: North America Market Value (USD Million) (2025-2032) By Types

Table 72: Europe Market Value (USD Million) (2025-2032) By Country

Table 73: Europe Market Value (USD Million) (2025-2032) By Application

Table 74: Europe Market Value (USD Million) (2025-2032) By Types

Table 75: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 76: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 77: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 78: South America Market Value (USD Million) (2025-2032) By Country

Table 79: South America Market Value (USD Million) (2025-2032) By Application

Table 80: South America Market Value (USD Million) (2025-2032) By Types

Table 81: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 82: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 83: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 84: Global Drugs for HAE Market Volume (K) By Region

Table 85: Global Drugs for HAE Market Share (%) By Region (2025-2032)

Table 86: North America Market Volume (K) (2025-2032) By Country

Table 87: North America Market Volume (K) (2025-2032) By Application

Table 88: North America Market Volume (K) (2025-2032) By Types

Table 89: Europe Market Volume (K) (2025-2032) By Country

Table 90: Europe Market Volume (K) (2025-2032) By Application

Table 91: Europe Market Volume (K) (2025-2032) By Types

Table 92: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 93: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 94: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 95: South America Market Volume (K) (2025-2032) By Country

Table 96: South America Market Volume (K) (2025-2032) By Application

Table 97: South America Market Volume (K) (2025-2032) By Types

Table 98: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 99: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 100: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 101: Research Programs/Design For This Report

Table 102: Key Data Information From Secondary Sources

Table 103: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Drugs for HAE Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	4.80 million
Revenue forecast in 2033	8.95 million
Growth rate	CAGR of 8.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Takeda Pharmaceuticals; BioCryst Pharmaceuticals; CSL Behring; Pharming Healthcare
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Drugs for HAE Segmentation Breakdown8 items

Application

Hospital and Clinic

Pharmacy

Other

Types

C1 Esterase Inhibitors

Kallikrein Inhibitors

Bradykinin Receptor Antagonist

Regional Insights

Loading chart…

Competitive Landscape

Takeda Pharmaceuticals: regional expansion

BioCryst Pharmaceuticals: innovation pipeline

CSL Behring: premium pricing

Pharming Healthcare: local manufacturing

Takeda Pharmaceuticals: vertical integration

BioCryst Pharmaceuticals: OEM tie-ups

Key Drugs for HAE Companies4 items

Takeda Pharmaceuticals

BioCryst Pharmaceuticals

CSL Behring

Pharming Healthcare

Market Ecosystem

Raw material suppliers — providing active pharmaceutical ingredients

OEMs/manufacturers — producing finished drug products

Technology providers — developing drug delivery systems

Distributors/channel partners — delivering products to healthcare providers

Service providers/after-sales — offering patient support services

Regulators/standards bodies — overseeing drug approvals and compliance

End users/buyers — patients and healthcare professionals

Recent Industry Insights

Analyst Overview

Table of Contents